synovial sarcoma (Cancer)
Information
- Disease name
- synovial sarcoma
- Disease ID
- DOID:5485
- Description
- "A synovium cancer which develops in the synovial membrane of the joints." [url:http\://en.wikipedia.org/wiki/Synovial_sarcoma, url:http\://www.cancer.gov/dictionary?cdrid=44626]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03016819 | Active, not recruiting | Phase 3 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | August 15, 2017 | June 2025 |
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT04420975 | Active, not recruiting | Phase 1 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | October 29, 2020 | January 31, 2026 |
| NCT02869217 | Active, not recruiting | Phase 1 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | September 2016 | September 2024 |
| NCT03132922 | Active, not recruiting | Phase 1 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | May 15, 2017 | September 2032 |
| NCT01241162 | Completed | Phase 1 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | August 2010 | October 2016 |
| NCT04537715 | Completed | Phase 1 | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | April 23, 2020 | April 3, 2023 |
| NCT00837148 | Completed | Phase 2 | Sorafenib and Dacarbazine in Soft Tissue Sarcoma | February 2009 | November 2013 |
| NCT01674101 | Completed | N/A | Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy | September 2012 | November 2015 |
| NCT02181829 | Completed | Phase 2 | Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases | July 2014 | June 24, 2020 |
| NCT03250325 | Completed | Phase 1/Phase 2 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma | September 20, 2017 | March 9, 2022 |
| NCT02584309 | Completed | Phase 2 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | February 22, 2016 | July 17, 2022 |
| NCT02601937 | Completed | Phase 1 | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | January 7, 2016 | October 22, 2021 |
| NCT02601950 | Completed | Phase 2 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | December 22, 2015 | February 26, 2024 |
| NCT00004853 | Completed | Phase 1 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | March 3, 2000 | May 20, 2009 |
| NCT00356031 | Completed | Phase 2 | Bevacizumab and Radiation Therapy for Sarcomas | July 2006 | March 2010 |
| NCT00668148 | Completed | Phase 2 | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma | July 2008 | February 2012 |
| NCT02875548 | Enrolling by invitation | Phase 1/Phase 2 | A Study to Assess the Long-term Safety of Tazemetostat | August 30, 2016 | November 3, 2025 |
| NCT03874455 | No longer available | Tazemetostat Expanded Access Program for Adults With Solid Tumors | |||
| NCT06456359 | Not yet recruiting | Phase 2 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor | September 2024 | October 2028 |
| NCT06277154 | Not yet recruiting | Phase 2 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | February 2024 | February 2027 |
| NCT05492682 | Recruiting | Phase 1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | February 2, 2023 | September 2025 |
| NCT05642455 | Recruiting | Phase 1/Phase 2 | SPEARHEAD-3 Pediatric Study | September 1, 2023 | July 30, 2038 |
| NCT05848739 | Recruiting | Phase 1 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | June 5, 2023 | May 31, 2027 |
| NCT05910307 | Recruiting | Synovial Sarcoma Registry / Biospecimen Repository | June 12, 2023 | June 2033 | |
| NCT06083883 | Recruiting | Phase 1 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | March 27, 2024 | November 30, 2028 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT04008238 | Recruiting | N/A | Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients | January 6, 2020 | January 2025 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04044768 | Recruiting | Phase 2 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | August 13, 2019 | April 1, 2038 |
| NCT04995003 | Recruiting | Phase 1 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | December 7, 2021 | December 31, 2040 |
| NCT06094101 | Recruiting | Phase 1/Phase 2 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) | September 19, 2023 | September 2027 |
| NCT05355753 | Terminated | Phase 1/Phase 2 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | March 25, 2022 | December 19, 2023 |
| NCT04145700 | Terminated | Phase 1/Phase 2 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | March 4, 2020 | February 23, 2023 |
| NCT02609984 | Terminated | Phase 2 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | April 29, 2015 | February 6, 2019 |
| NCT03604783 | Terminated | Phase 1 | Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | December 26, 2018 | January 10, 2024 |
| NCT03399448 | Terminated | Phase 1 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | September 5, 2018 | October 9, 2020 |
| NCT02683148 | Terminated | Phase 1 | DHEA in Synovial Sarcoma Patients | September 13, 2016 | April 4, 2019 |
| NCT03520959 | Terminated | Phase 3 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | September 18, 2018 | November 20, 2018 |
| NCT01957709 | Terminated | Early Phase 1 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | September 25, 2013 | June 1, 2018 |
| NCT00140855 | Terminated | Phase 2 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | June 8, 2005 | July 1, 2007 |
| NCT02983539 | Unknown status | Detection of Circulating Tumor Cells in Patients With Sarcomas | October 2015 | June 2018 | |
| NCT03638206 | Unknown status | Phase 1/Phase 2 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | March 1, 2018 | March 1, 2023 |
| NCT03651375 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | February 11, 2017 | March 2022 |
| NCT03989596 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas | June 1, 2018 | December 31, 2022 |
| NCT02457650 | Unknown status | Phase 1 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | April 2015 | December 2019 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT03773510 | Withdrawn | Phase 3 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | February 28, 2019 | October 1, 2025 |
- Disase is a (Disease Ontology)
- DOID:2706
- Cross Reference ID (Disease Ontology)
- GARD:7721
- Cross Reference ID (Disease Ontology)
- ICDO:9040/3
- Cross Reference ID (Disease Ontology)
- MESH:D013584
- Cross Reference ID (Disease Ontology)
- MIM:300813
- Cross Reference ID (Disease Ontology)
- NCI:C3400
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:63211008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0039101
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012570
- OrphaNumber from OrphaNet (Orphanet)
- 3273